“Cuban Abdala Vaccine Phase 3 Clinical Trial Results Published in The Lancet Regional Health-Americas”

The prestigious British magazine The Lancet Regional Health-Americas has published a scientific article on the results of the phase 3 clinical trial of the Cuban Abdala vaccine (Center for Genetic Engineering and Biotechnology).

The publication indicates that the trial demonstrated the safety, tolerability and vaccine efficacy of 92.28% against symptomatic disease due to covid-19 and 92.88% against moderate/severe forms of the disease. There were no critical patients or deaths in the group that received the Abdala vaccine.

The study was developed in 18 clinical sites in the provinces of Santiago de Cuba, Guantánamo and Granma, with the participation of 48,290 volunteers from 19 to 80 years of age.

These results allowed the authorization for emergency use of Abdala and its use in mass vaccinations, with a direct impact on the control of the pandemic in the Cuban population.

In the article (“Evaluation of randomized, double-blind, placebo-controlled clinical trials of the efficacy and safety of a vaccine against the recombinant RBD spike protein SARS-CoV-2 in adults. Study ABDALA-3”), it is highlighted that “ The Abdala vaccine was safe, well tolerated, and highly effective, meeting the WHO target product profile for covid-19 vaccines.

“These results, together with its immunization schedule and the advantage of easy storage and handling conditions at 2-8 °C, make this vaccine an option for use in immunization strategies as a key tool for pandemic control.” .

(With information from The Lancet Regional Health-Americas)